Key facts
- It has raised $22.1M; the latest was IPO ($16.8M) in Jul 2025.
- Notable investors include Tech Incubator Program for Startup, SparkLabs Group, Shinhan Venture Investment, Kiwoom Investment, Bluepoint Partners — 17 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for QuadMedicine
- ·The full record, as it builds
Funding rounds
No funding rounds for QuadMedicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About QuadMedicine
Developer of microneedle vaccine designed to improve the quality of life through advanced microarray patch technologies. The company's microarray patch-specific formulations can maximize the stability and efficacy of application programming interfaces during manufacturing and storage, enabling the medical industry with a painless and safe way to deliver vaccines transdermally.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2016
- Employees
- 86
- Website
- quadmedicine.com/en
- Ownership
- In IPO Registration
QuadMedicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in QuadMedicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on QuadMedicine in its N-PORT filings yet. We sweep new filings monthly.